FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis | Synapse
November 14, 2024Open Access
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
Key Points
Key points are not available for this paper at this time.
Abstract
Rates of skin clearance with JNJ-77242113 were durable to 1 year and no safety signals were identified.